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The primary products of the metastasis-suppressor KiSS-1 gene are the kisspeptin (KP) peptides that stimulate gonadotrophin-
releasing-hormone (GnRH) release via GPR-54 receptor activation. Recent studies have suggested that the KP-10 peptide also
activates neuropeptide FF (NPFF) receptors. The aim of the current study was to determine the activities of the KiSS-1 derivative
kissorphin (KSO), which contains the first six amino acids of the KP-10 peptide, is C-terminally amidated, and shares amino
acid similarities with the biologically active NPFF 3–8 sequence. The KSO peptide inhibited forskolin-stimulated cyclic adenosine
monophosphate (cAMP) production in ND7/23 neuroblastoma cells via an action that could be inhibited by the NPFF receptor
antagonist RF9. Release of GnRH by LA-N-1 neuroblastoma cells was not altered by the KSO peptide. In ND7/23 neuroblastoma
cells, the KSO peptide was able to reduce forskolin neuroprotection against H2O2 toxicity. The KSO peptide was also able to
prevent prostaglandin E2-induced apoptosis in rat cortical neurons. The NPFF receptor antagonist RF9 could inhibit these actions
of the KSO peptide in oxidative stress and apoptosis models. In conclusion, the kissorphin peptide, comprising the amino acid
sequence Tyr-Asn-Trp-Asn-Ser-Phe-NH2, has NPFF-like biological activity without showing any GnRH releasing activity and
inhibits forskolin-activated cAMP release.
1. Introduction
Recent studies have shown that kisspeptin (KP) peptides can
activate the two neuropeptide FF (NPFF) receptors, NPFFR1
(GPR-147) and NPFFR2 (GPR-74) [1–3]. These actions of
KP peptides can be blocked by NPFF receptor antagonists
including RF9 [4]. The NPFF peptide is a ligand for both
these receptors [5–7], and the biologically active NPFF 3–
8 form [8] shows amino acid sequence similarities to KP
peptides (Table 1).
The KP peptides themselves play a central role in
the hypothalamic-pituitary-gonadal (HPG)-axis by acting
on gonadotrophin-releasing hormone (GnRH) neurons to
activate GnRH release [9]. The KP peptides are encoded by
the metastasis-suppressor KiSS-1 gene and are ligands for
the GPR-54 receptor [1, 10–12]. A range of KP peptides are
found in vitro and in vivo with the largest 54 amino acid form
corresponding toresidues 68–121 of the KiSS-1 encoded pre-
pro-KP [10]. Shorter derivatives of KP comprising the C-
terminal 14, 13, and 10 amino acids have also been found
in tissues and corresponding to residues 108–121, 109–121,
and 112–121 of the KiSS-1 encoded pre-pro-KP [10, 13].
Biological activity of KP peptides requires the KP 112-121
sequence with an amidated C-terminus [10, 13, 14].
The biological activities of NPFF include antiopioid [8,
15], analgesic [16], anorexigenic [17, 18], cardiovascular
[19, 20], adipocyte [21], and immune cell [22] eﬀects.
The biological activities of NPFF involve an action that
can be measured as inhibition of forskolin-stimulated cyclic
adenosine monophosphate (cAMP) production and are
mediated via activation of the NPFFR1 or NPFFR2 receptors
[23–25].
Cleavage of KP peptides to remove the amidated C-
terminal tripeptide Leu-Arg-Phe-NH2 of the KP sequence
by matrix metalloproteinase (MMP) enzymes abolishes the
activation of GPR-54 by KP peptides [26]. However, the
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Table 1: Comparison of kisspeptin, kissorphin, and NPFF sequences.
Kisspeptin-13 Leu Pro Asn Tyr Asn Trp Asn Ser Phe Gly Leu Arg Phe NH2
Kisspeptin-10 Tyr Asn Trp Asn Ser Phe Gly Leu Arg Phe NH2
Kissorphin Tyr Asn Trp Asn Ser Phe NH2
Neuropeptide FF Phe Leu Phe Gln Pro Gln Arg Phe NH2
∗ † ∗ † ∗
∗
Ring structure aminoacid; †uncharged polar aminoacid.
resultant peptides have a C-terminal glycine residue that
could be alpha-amidated [27] and C-terminal alpha amida-
tion is a feature of many biologically active neuropeptides.
As such the MMP cleaved KP peptides could have an
alternative biological activity. In view of the similarities
between KP and NPFF sequences it is possible that the
hexapeptide fragment of KP-10 containing residues 1–6
with a C-terminally amidated phenylalanine residue could
have NPFF-like activity. The aim of the study has been to
determine if the KP derivative Tyr-Asn-Trp-Asn-Ser-Phe-
NH2, termed kissorphin (KSO), has biological activity and to
determine whether KSO peptides have NPFF-like activities in
neuronal cell culture-based assays.
2. Materials and Methods
2.1. Materials. Synthetic NPFF, KP, and KSO peptides were
obtained from Bachem. Mouse neuroblastoma x rat neuron
hybrid ND7/23 [28] and human LA-N-1 neuroblastoma [29]
cell lines were obtained from the Health Protection Agency,
Cell Culture Collection. Rat cortical neurons and cell culture
media were obtained from Invitrogen. The cAMP EIA kits
and other test chemicals were obtained from Sigma-Aldrich.
2.2. Cell Cultures. Mouse neuroblastoma x rat neuron hybrid
ND7/23 and human LA-N-1 neuroblastoma cells were
routinely grown in a 5% CO2 humidified incubator at 37◦C
in a 1 : 1 mixture of Dulbecco’s modified Eagle’s medium and
HAM’s F12 with Glutamax (Invitrogen) supplemented with
10% foetal calf serum (FCS), 1% nonessential amino acids,
penicillin (100 units/ml), and streptomycin (100mg/ml)
[30–32]. Primary cultures of rat cortical neurons were
prepared from cryopreserved rat cortex neurons [33] isolated
from day-18 Fisher 344 rat embryos and cultured according
to the supplier instructions in Neurobasal/B27 medium.
2.3. Inhibition of Forskolin Stimulated cAMP Assays. ND7/23
cells were plated onto 24-well plates in normal growth
medium and cultured overnight. The medium was replaced
with serum-free medium containing 100 μM IBMX on the
day of the experiment for 2 h prior to the addition of test
compounds [3, 34]. Cells were then treated with medium
alone (control) or medium containing 10 μM forskolin and
100 μM IBMX and varying doses (10 nM–100 μM) of the
synthetic NPFF, KP, or KSO peptides. Cells were then incu-
bated at 37◦C for a total of 30min, after which the medium
was aspirated and replaced with a 1ml of 0.1M HCl and
incubated for 15min to stop the reaction and lyse the cells.
Cell lysates were centrifuged to remove cellular debris and
cAMP levels in the supernatant determined. The ir-cAMP
levels were determined using a direct enzyme immunoassay
kit according to the manufacturers instructions. Samples
and standards were acetylated prior to incubation with anti-
cAMP antibody and cAMP-alkaline phosphatase conjugate.
2.4. GnRH Release Assay. LA-N-1 cells were plated onto
24-well plates in normal growth medium and cultured
overnight. On the day of experiment, cells were then treated
with medium alone (control) or medium containing varying
doses (10 nM–10 μM) of the synthetic NPFF, KP, or KSO
peptides. Cells were then incubated at 37◦C for a total
of 2 hours, after which the medium was aspirated for
determination of GnRH levels. The immunoreactive (ir)
GnRH was measured by EIA using synthetic biotinyl-GnRH-
I, GnRH-I standards, primary anti-GnRH antibody coated
immunoplates, and detection with streptavidin labeled HRP
and TMB substrate.
2.5. Forskolin Neuroprotection against Hydrogen Peroxide
(H2O2) Toxicity. ND7/23 cells were plated onto 96-well
plates in normal growth medium and cultured overnight.
On the day of the experiment cells were treated with
combinations of media alone (control), H2O2 (250 μM) to
induce toxicity, forskolin (10 μM) to protect against H2O2
toxicity [35], and 10 μM NPFF, KP, or KSO peptides. Cells
were incubated for 2 hours prior to determination of cell
viability.
2.6. Prostaglandin-E2 (PGE2) Toxicity. Rat cortical neurons
were plated onto 96-well plates in normal growth medium.
On the day of the experiment, cells were treated with
media alone (control), PGE2 (25 μM) to induce toxicity
[36], and either 10 μM NPFF, KP, or KSO peptides. Cells
were incubated for 24 hours prior to determination of cell
viability.
2.7. Cell Viability. After treatment with test peptides or drugs
and incubation for the appropriate time the viability was
determined by either trypan blue dye exclusion with at least
100 cells counted per well or by MTT reduction [37]. For
MTT reduction determination, after incubation with test
substances MTT (10 μl : 12mM stock) was added and cells
incubated for a further 4 hours. Cell lysis buﬀer (100 μl/well;
20% (v/v) SDS, 50% (v/v) N,N-dimethylformamide, and
pH 4.7) was added and after repeated pipetting to lyse cells
the MTT formazan product formation was determined by
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Figure 1: Eﬀect of KSO, NPFF, and KP peptides on forskolin-
stimulated ir-cAMP release from ND-7/23 cells. Cells were exposed
to forskolin with KSO, NPFF, or KP peptides for 30min prior to
termination of the reaction with 0.1MHCl. The eﬀects of the NPFF
receptor antagonist RF9 and the GPR-54 antagonist KP234 on KSO,
NPFF, or KP peptide inhibition of forskolin-stimulated ir-cAMP
release were also determined. Levels of ir-cAMP in the cell lysates
were measured by EIA. Results are mean ± sem (n = 8). ∗P < 0.05
versus forskolin alone; †P < 0.05 versus KSO, NPFF, or KP peptide
alone; one-way ANOVA.
measurement of absorbance change at 570 nm. Control levels
in the absence of test substances were taken as 100%, and the
absorbance in the presence of cells lysed with Triton X-100
at the start of the incubation period with test substances was
taken as 0% [38].
2.8. Data Analysis. All data are expressed as means ±
s.e.m. For irGnRH measurements levels in samples were
determined from a standard curve using synthetic GnRH-I as
the standard. For cytotoxicity experiments data are expressed
as% dead (trypan blue stained) cells or % control cells (MTT
reduction). The significance of diﬀerences between data was
evaluated by one-way analysis of variance (ANOVA). A P
value of <0.05 was considered statistically significant.
3. Results
3.1. Eﬀect of KSO Peptides on NPFF-Like Biological Activ-
ity. The NPFF-like biological activity was determined by
measurement of forskolin-stimulated ir-cAMP release in
response to KSO, KP, and NPFF peptides. The KSO peptides
containing residues 1–6 and 3–6 significantly inhibited
forskolin stimulated ir-cAMP release from ND-7/23 cells
(Figure 1), whilst the KSO 1-3 fragment had no eﬀect.
The NPFF, KP-10, and KP-13 peptides also significantly
inhibited forskolin stimulated ir-cAMP release, which could
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Figure 2: Eﬀect of KSO, NPFF, and KP peptides on irGnH release
from LA-N-1 neuroblastoma cells. Cells were exposed to KSO,
NPFF, KP, the NPFF receptor antagonist RF9, and the GPR-54
antagonist KP234 for 2 hours. Levels of irGnRH in the media were
measured by EIA. Results are mean ± s.e.m. (n = 8). ∗P < 0.05
versus control (media alone); †P < 0.05 versus KP peptide alone;
one-way ANOVA.
be antagonized by the NPFF receptor antagonist RF-9 [4] but
not the GPR-54 receptor antagonist KP234 [39]. The RF-9
and KP234 had no eﬀect on forskolin-stimulated ir-cAMP
release.
3.2. Eﬀect of KSO Peptides on KP-Like Biological Activity. The
KP-like biological activity was determined by measurement
of irGnRH release in response to KSO, KP, and NPFF
peptides. The KSO peptides containing residues 1–6, 1–
3 and 3–6 had no eﬀect on irGnRH release from LA-N-
1 neuroblastoma cells (Figure 2). The KP-10 and KP-13
peptides both stimulated a significant increase in irGnRH
release, which could be antagonized by the GPR-54 receptor
antagonist KP234 [39] but not the NPFF receptor antagonist
RF-9 [4]. The KSO peptides had no eﬀect on KP stimulated
irGnRH release. NPFF, RF-9, and KP234 had no eﬀect on
irGnRH release.
3.3. Eﬀect of KSO Peptides on H2O2 and PGE2 Neurotoxicity.
The eﬀects of KSO peptides were tested in two models of
neurotoxicity. In the H2O2-stimulated-toxicity model the
KSO 1–6 and 3–6 peptides, plus NPFF and KP-10 peptides,
inhibited the forskolin protection against H2O2 toxicity in
ND-7/23 cells (Figure 3). These eﬀects could be reversed
by the NPFF receptor antagonist RF-9 but not the GPR-54
antagonist KP234. In the PGE2-induced-toxicity model the
KSO 1-6 and 3-6 peptides, plus NPFF and KP-10 peptides,
were able to reduce the PGE2 toxicity (Figure 4). These eﬀects
could be reversed by the NPFF receptor antagonist RF-9 but
not the GPR-54 antagonist KP234.
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Figure 3: Eﬀect of KSO, NPFF, and KP peptides on forskolin
prevention of H2O2 toxicity in ND-7/23 cells. Cells were exposed to
H2O2 either alone or in the presence of forskolin with KSO, NPFF,
or KP peptides for 2 hours prior determination of cell viability by
MTT reduction. The eﬀects of the NPFF receptor antagonist RF9
and the GPR-54 antagonist KP234 were also determined. Results
are expressed as % Control MTT reduction (mean ± sem; n = 8).
∗P < 0.05 versus H2O2 alone; †P < 0.05 versus H2O2 plus forskolin;
one-way ANOVA.
4. Discussion
The results show that the KSO peptide has biological activity
in neuronal cell models that can be antagonized by the
NPFF receptor antagonist RF-9 [4] but not the GPR-54
receptor antagonist KP234 [39]. The actions of KSO involve
inhibition of stimulated cAMP release and are similar to
documented eﬀects for both NPFF [23, 40] and KP peptides
[1–3] in vitro. The NPFF receptors respond to a number
of RF-amide containing peptides [41], but this is the first
demonstration of a response to an SF-amide peptide. The
contribution of NPFFR1 and NPFFR2 receptors to the
observed eﬀects has not been tested. Both these receptors
react with NPFF [42] and KP peptides [2, 3], and it is
likely that KSO peptides will act on both receptor types.
The cross-reactivity of NPFF with some KP antibodies
[43] suggests shared tertiary structure similarity as well as
sequence similarity exists. The ability of NPFF, KP, and KSO
peptides to act in similar neuronal models suggests that
the KSO sequence represents the region of KP with NPFF
similarity. The distribution of NPFF receptors [23, 44–47]
suggests that the main eﬀects of KSO peptides is likely to
be restricted and there may also be species diﬀerences. The
specificity of the NPFF antagonist RF-9 [3, 4] used in this
study does not rule out actions via other related receptors.
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Figure 4: Eﬀect of KSO, NPFF, and KP peptides on PGE2 toxicity
in rat cortical neurons. Cells were exposed to PGE2 either alone
or in the presence of KSO, NPFF, or KP peptides for 24 hours
prior determination of cell viability by MTT reduction. The eﬀects
of the NPFF receptor antagonist RF9 and the GPR-54 antagonist
KP234 were also determined. Results are expressed as % Control
MTT reduction (mean ± s.e.m.; n = 8). ∗P < 0.05 versus control;
†P < 0.05 versus PGE2 alone; one-way ANOVA.
However, the actions of KSO are shared with NPFF and
KP peptides, suggesting that a common feature that RF-
9 can block mediates the eﬀects. Cell lines overexpressing
NPFFR1 and NPFFR2 receptors have been used to determine
receptor-binding aﬃnities and cAMP inhibition by NPFF
related peptides [6, 24, 42] and could be employed to confirm
KSO interactions with NPFF receptors.
The ability of MMP enzymes to cleave KP-10 in vitro
[26] to yield the KSO sequence, with an extra C-terminal Gly
residue that can be amidated [27], raises the possibility that
KSO-like peptides could be generated both in vitro and in
vivo. The observations that KP peptides down regulate the
expression of MMP enzymes [48] suggest that this action
may be limited by release of KP peptides. However, there are
conditions where MMP enzymes are elevated, and since the
eﬀects of KP peptides are at the level of protein expression
rather than activity, there may be conditions where KSO-like
peptides could be generated. The KSO sequence and MMP
cleavage sites in the KiSS-1 precursor protein are shared
between the human [10, 13] and rat forms [49]. It cannot
be excluded that the actions of KP-10 and KP-13 in the cell
models tested are due to generation of KSO-like peptides.
The ability of KSO peptides to prevent PGE2 toxicity
in rat cortical neurons raises the possibility that KSO
peptides could be neuroprotective; however, the reversal of
forskolin neuroprotection by KSO peptides suggests that
any neuroprotective properties may be model specific. The
expression of appropriate NPFF or related receptors that
KSO peptides can bind to and activate responses from may
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also be key for neuroprotective activity. In a recent study
the KP peptides including the KSO 1–6 fragment were
shown to be neuroprotective against amyloid peptides via
a receptor-independent mechanism [50]. The results with
the reversal of forskolin neuroprotection suggest that in
vivo the KSO peptides could have multiple actions and
therefore not show measurable neuroprotective properties.
The requirement for doses in the μM range suggests that
the eﬀects being observed may not be seen at physiological
concentrations of endogenous KSO peptides.
The lack of GnRH releasing activity of the KSO peptides
is in agreement with previous studies [26]. The KSO peptide
used in the present study has an amidated C-terminus
instead of the glycine residue used in the Takino et al.
[26] study, however, this has not added a GnRH releasing
bioactivity.
5. Conclusions
The present study has identified a biological activity as an
inhibitor of stimulated cAMP release for the KSO peptides
with the sequences Tyr-Asn-Trp-Asn-Ser-Phe-NH2 and Trp-
Asn-Ser-Phe-NH2, which can be antagonized by an NPFF
receptor antagonist. These actions are seen in neuronal cell
models based on human,mouse, and rat cells, suggesting that
the action is not species specific.
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